New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

47
Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

description

New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective. Question. NCCN Guideline Recommendations Selected Salvage Therapy Regimens. Question. Multiple Myeloma Supportive Care . Question. Question. Question & Answer Session. Abbreviations. - PowerPoint PPT Presentation

Transcript of New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Page 1: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

New and Emerging Approaches in Relapsed or Refractory Myeloma:

The Pharmacist’s Perspective

Page 2: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 3: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 4: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 5: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Question

Page 6: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 7: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 8: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

NCCN Guideline Recommendations

Selected Salvage Therapy Regimens

Page 9: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 10: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Question

Page 11: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 12: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 13: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 14: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 15: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 16: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 17: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 18: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 19: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 20: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 21: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 22: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 23: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Multiple MyelomaSupportive Care

Page 24: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 25: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 26: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Question

Page 27: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 28: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 29: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 30: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Question

Page 31: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 32: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 33: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 34: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 35: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 36: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 37: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 38: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective
Page 39: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Question & Answer Session

Page 40: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Abbreviations

Page 41: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Abbreviations (cont)

Page 42: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

Abbreviations (cont)

Page 43: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

References

Page 44: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

References (cont)

Page 45: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

References (cont)

Page 46: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

References (cont)

Page 47: New and Emerging Approaches in Relapsed or Refractory Myeloma: The Pharmacist’s Perspective

References (cont)